2. Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor
  3. LXR
  4. TLC-2716

TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ, with EC50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders.

For research use only. We do not sell to patients.

TLC-2716

TLC-2716 Chemical Structure

Size Price Stock
1 mg Ask For Quote & Lead Time
5 mg Ask For Quote & Lead Time
10 mg Ask For Quote & Lead Time
25 mg Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of TLC-2716:

TLC-2716 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ, with EC50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders[1].

IC50 & Target[1]

LXRα

7 nM (EC50)

LXRβ

15 nM (EC50)

In Vitro

TLC-2716 (1 h at 4 °C) binds to recombinant human LXRα (EC50 = 7 nM) and LXRβ (EC50 = 15 nM) in a biochemical binding assay[1].
TLC-2716 (16 h) induces NCOR recruitment to LXRα and LXRβ with EC50 values of 8 nM and 11 nM in HEK293 mammalian two‑hybrid assays, and inhibits ABCA1 and SREBP1c reporter activities with IC50 values of 15 nM and 7 nM in HT‑29 and HepG2 cells, respectively[1].
TLC-2716 (5 days) dose-dependently reduces intracellular triglyceride accumulation in primary human Upcyte hepatocytes with an EC50 of 289 nM[1].
In steatotic human liver organoids, TLC-2716 (500 nM-5 μM; 3 days) dose-dependently reduces intracellular lipid content and suppresses expression of LXR-associated, lipid metabolism, inflammation, and fibrosis-related genes, with enhanced effects in GCKRTT organoids[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

TLC-2716 Related Antibodies
In Vivo

TLC-2716 (0.3-1 mg/kg; oral gavage; once daily; 3 weeks) dose-dependently improves dyslipidemia in high-fat diet-induced obese mice by reducing hepatic de novo lipogenesis, liver TG content, and plasma TG and TC levels without impairing peripheral reverse cholesterol transport[1].
TLC-2716 (0.1-15 mg/kg; p.o.; daily) reduces dyslipidemia-related endpoints and improves glucose homeostasis in ZDF rats without impairing liver function[1].
TLC-2716 (0.1-1 mg/kg; p.o.; daily; 21 days) reduces hepatic DNL gene expression, liver TG, and plasma TG and TC in high-fat diet-fed SD rats without impairing liver function[1].
TLC-2716 (1 mg/kg; p.o.; daily; 8 days) reduces hepatic expression of lipid metabolism genes and trends to reduce liver TG in human liver chimeric mice[1].
TLC-2716 (15-120 mg/kg; oral gavage; once daily; 26 weeks) reduces plasma TG and TC in lean CD-1 mice without causing observable adverse effects[1].
TLC-2716 (1-15 mg/kg; oral gavage; once daily; 28 days) reduces plasma TG and TC in cynomolgus monkeys without causing observable adverse effects[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (male, 18 weeks old, diet-induced obese via 14 weeks high-fat diet)[1]
Dosage: 0.3 mg/kg; 1 mg/kg
Administration: p.o.; daily; 21 days
Result: Dose-dependently reduced hepatic expression of de novo lipogenesis (DNL) genes including Scd1, Fasn, Srebp1c and Acaca.
Decreased liver triglyceride (TG) content as well as area under the curve (AUC) values for plasma TG and total cholesterol (TC) at 1 mg/kg, with milder reductions observed at 0.3 mg/kg.
Maintained comparable plasma alanine transaminase (ALT) and aspartate aminotransferase (AST) levels versus vehicle treatment.
Dose-dependently downregulated ileal Srebp1c expression.
Animal Model: Zucker diabetic fatty (ZDF) (male, 6-7 weeks old, obese fa/fa)[1]
Dosage: 0.1 mg/kg; 1 mg/kg; 15 mg/kg
Administration: p.o.; daily; 14 days (0.1, 1 mg/kg); p.o.; daily; 28 days (15 mg/kg)
Result: Reduced hepatic DNL gene expression, liver TG content, and AUC for plasma TG and TC at 0.1 and 1 mg/kg.
Reduced fasting plasma glucose by approximately 56% and lowered hepatic Angptl3 expression and plasma ANGPTL3 levels at 15 mg/kg.
Remained unchanged plasma ALT and AST levels relative to vehicle.
Animal Model: Sprague-Dawley (SD) (male, 6-7 weeks old, high-fat diet-induced obese)[1]
Dosage: 0.1 mg/kg; 1 mg/kg
Administration: p.o.; daily; 21 days
Result: Reduced hepatic DNL gene expression, liver TG content, and AUC for plasma TG and TC at both doses.
Remained unchanged plasma ALT and AST levels relative to vehicle.
Animal Model: PXB (male, humanized liver chimeric)[1]
Dosage: 1 mg/kg
Administration: oral gavage; once daily; 8 days
Result: Trended to reduce liver TG content.
Reduced hepatic expression of cholesterol synthesis gene HMGCR, lipid clearance gene ANGPTL3, and de novo lipogenesis genes SREBP1C, FASN, ACACA, SCD1.
Animal Model: CD-1 (male and female, lean)[1]
Dosage: 15 mg/kg; 60 mg/kg; 120 mg/kg
Administration: p.o.; daily; 182 days
Result: Reduced plasma TG and TC in both male and female mice at all doses.
Observed no adverse clinical observations, liver biochemistry changes, or histopathological signs of liver injury at any dose.
Molecular Weight

739.12

Formula

C38H22ClF3N4O5S
SMILES

OC(CNC(C1=CC=C(C2=CC(C3=C(C4=C(C#N)C=CC=C4C#N)C5=CC(F)=CC=C5N3S(C6=CC=C(C(F)F)C=C6)(=O)=O)=CC=C2)C(Cl)=C1)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

TLC-2716 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TLC-2716TLC2716TLC 2716LXRLiver X receptorLXRαhuman liver organoidsHEK293 cellsLXRβcynomolgus monkeysHT-29 cellsprimary human Upcyte hepatocytesDIO miceHepG2 cellsZDF ratsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
TLC-2716
Cat. No.:
HY-182014
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.